HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
about
Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patientsProgress toward overcoming hypoxia-induced resistance to solid tumor therapyMaximizing the Therapeutic Potential of HSP90 InhibitorsThe G protein α chaperone Ric-8 as a potential therapeutic targetExtracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionallyBeyond BRAF: where next for melanoma therapy?Profile of neratinib and its potential in the treatment of breast cancerAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerCo-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 InhibitorsSynthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2The rebel angel: mutant p53 as the driving oncogene in breast cancer.Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerAmplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancerPosttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitorsA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionConnecting gene expression data from connectivity map and in silico target predictions for small molecule mechanism-of-action analysis.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.Evaluating melanoma drug response and therapeutic escape with quantitative proteomicsCurrent Approaches and Emerging Directions in HER2-resistant Breast Cancer.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsGetting folded: chaperone proteins in muscle development, maintenance and disease.Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsThe HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsChange or die: targeting adaptive signaling to kinase inhibition in cancer cells.Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance SpectroscopyTreating breast cancer in the 21st century: emerging biological therapiesUpregulation of heat shock factor 1 transcription activity is associated with hepatocellular carcinoma progression.A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.Induced protein degradation: an emerging drug discovery paradigm.Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
P2860
Q26752024-A22D62E9-B1B8-4D5E-B2B3-586093D29A4FQ26796405-E35383BB-049E-4641-B8D9-2C5D21E37020Q26798318-3A7EF622-47EA-4E0C-850E-2ABE18329B5CQ26824363-036BEA93-88B8-4719-86B7-DBE70DF5EC41Q26991472-815B16CE-8D78-45F1-AB26-23AF49CB26D2Q27006853-D20FF62F-404F-408F-A093-490969F7FA6FQ27012540-E16F95AD-75CF-40CA-8F6C-909847CB847FQ27022514-DC1DEC5E-24CB-4D67-80EC-B3D6988BE016Q27025863-F00BBE06-FB7B-46F4-AFA5-AF6914630A49Q27673253-9E6A8DD0-E3FB-4E6E-928D-1960773FE194Q27676888-2E6526D4-63C1-46F1-8D56-6628368EA1C9Q27679845-495A628A-F4B1-498B-A71D-9B68DDC658CBQ27686765-CE6016DA-D34C-45AB-A300-69C1AE141D1DQ28072513-63AC3402-DF1D-41D1-923E-CE17CCC3A46DQ28264693-D0DB5609-57AE-47FE-99CE-8008E407935DQ28294781-42A33815-6870-4905-BAD6-8D601B5C85C1Q28598343-7832B598-C543-45A5-BEE4-E0E833D559A9Q28829301-C07E85B4-7CE6-4DF8-B65A-01389A9C34EBQ30855130-E4460EF4-9E6E-4BBF-8CDA-1185C972B642Q30857631-55881A01-3940-49F1-845B-D00354E93048Q31103913-B30ED41D-BA66-45B9-BE07-59ACBFD71F2AQ33584583-2E6087CB-ED2C-4929-9E64-FDBFAD7D9A9FQ33688577-421BA028-7A03-452D-B1C7-E0BF0E88D685Q33765280-E61C257A-516F-4032-93A0-41DD935CF36AQ33850665-0A615449-FBA7-4EB7-B21D-317F345E82A2Q34016480-2C4F7D14-E924-457C-A44F-43F41008484BQ34023704-5F008751-F074-489B-A293-30293E6C09F7Q34055646-732C1E91-BA23-46E5-9718-24FA2017F92FQ34100283-2BDE6B9D-D546-45D8-AF0E-F56D16D9A9E0Q34164027-1C3664D2-DF1B-4A21-8BBE-61F59B33B3C0Q34165045-84882181-1074-49A9-8F52-D366005BD642Q34225871-2EA1CEF8-FDE9-4B5E-92F5-2870029DFD45Q34278997-3EEADED9-ED16-4C86-8087-01CD7B8F7D2CQ34326536-473F4AC4-4D7D-43A8-A37F-2B5F368DB92CQ34426830-C772F003-4064-470D-98DB-C169AB27BEF9Q34430965-E0499F60-7C6A-4A32-A528-FE55774A2858Q34545841-ADB18622-8B5D-42B6-9F2C-29D81934B219Q34629026-40C88404-4EDD-4D15-8AB3-6AA83C3EBC7BQ34664129-47985441-1A12-479A-9828-A0C86EF147B7Q34852929-E7BC1693-E523-4322-A4F3-BE4A81DB85A1
P2860
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
HSP90 inhibition is effective ...... er progressing on trastuzumab.
@en
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin
@nl
type
label
HSP90 inhibition is effective ...... er progressing on trastuzumab.
@en
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin
@nl
prefLabel
HSP90 inhibition is effective ...... er progressing on trastuzumab.
@en
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin
@nl
P2093
P50
P1476
HSP90 inhibition is effective ...... cer progressing on trastuzumab
@en
P2093
Alison L Hannah
Alison Stopeck
Clifford Hudis
David Solit
Hannah Linden
Maura Dickler
Neal Rosen
Sarat Chandarlapaty
Steven Sugarman
Sujata Patil
P304
P356
10.1158/1078-0432.CCR-11-0072
P407
P577
2011-05-10T00:00:00Z